Aileron Therapeutics

Aileron Therapeutics logo
🇺🇸United States
Ownership
Public
Established
2005-01-01
Employees
15
Market Cap
$52.4M
Website
http://www.aileronrx.com

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

First Posted Date
2022-11-18
Last Posted Date
2023-02-27
Lead Sponsor
Aileron Therapeutics, Inc.
Target Recruit Count
6
Registration Number
NCT05622058
Locations
🇧🇬

MBAL University Hospital OOD, Panagyurishte, Bulgaria

🇺🇸

Southern Oncology Specialists, Huntersville, North Carolina, United States

🇺🇸

Oncology and Hematology Associates of West Broward, Tamarac, Florida, United States

and more 11 locations

A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection)

First Posted Date
2019-07-17
Last Posted Date
2022-10-10
Lead Sponsor
Aileron Therapeutics, Inc.
Target Recruit Count
35
Registration Number
NCT04022876
Locations
🇺🇸

Mount Sinai Cancer Research Program, Miami, Florida, United States

🇺🇸

Regional Medical Oncolgy Center, Wilson, North Carolina, United States

🇺🇸

Gabrail Cancer Institute, Canton, Ohio, United States

and more 25 locations

ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas

First Posted Date
2014-10-15
Last Posted Date
2020-07-14
Lead Sponsor
Aileron Therapeutics, Inc.
Target Recruit Count
149
Registration Number
NCT02264613

Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

First Posted Date
2013-01-25
Last Posted Date
2013-05-30
Lead Sponsor
Aileron Therapeutics, Inc.
Target Recruit Count
33
Registration Number
NCT01775358
Locations
🇺🇸

Vince and Associates Clinical Research, LLC, Overland Park, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath